• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Phar LLC

Partnership for Health Analytic Research, LLC

  • Services
    • Economic Modeling
    • Real World Data: Secondary Data Analysis
    • Evidence Synthesis
    • Real World Data: Primary Data Collection
  • Publications
  • Clients
  • Team
  • News
  • Contact

Primary Sidebar

News Categories

  • Presentations & Events
  • Awards & Recognition
  • Publications
  • News & Announcements

Archive

  • 2020
  • 2019
  • 2018
  • 2017

PHAR Projects Cost Savings from Hepatitis C Cures

Chronic Hepatitis C Virus (HCV) is a common infectious disease that affects 2.4 million people in the United States. The clinical and economic impact of HCV on the US healthcare system is significant. Direct-acting antiviral (DAA) treatments have been shown to provide a cure for HCV in most individuals, however there has been debate over the price. Building upon a recently published analysis, PHAR investigated the costs of using DAAs to treat individuals with HCV, and found there were substantial savings associated with decreased consequences of the disease, far exceeding the costs of the treatments themselves. A report summarizing these findings can be found here.

July 24, 2019 | News & Announcements

Partnership for Health Analytic Research, LLC

Beverly Hills
Cambridge
San Francisco
info@pharllc.com
310.858.9555
pharllc.com
  • Employment
  • Contact
Design by Studio Rainwater
© PHAR LLC 2021